Perceptive Advisors LLC reduced its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 66.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 414,684 shares of the biopharmaceutical company’s stock after selling 817,816 shares during the period. Perceptive Advisors LLC owned about 0.76% of Corbus Pharmaceuticals worth $2,964,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp boosted its position in Corbus Pharmaceuticals by 2,998.2% during the 2nd quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after buying an additional 569,662 shares during the period. Northern Trust Corp boosted its position in Corbus Pharmaceuticals by 814.3% during the 2nd quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after buying an additional 429,584 shares during the period. Vanguard Group Inc. boosted its position in Corbus Pharmaceuticals by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 307,979 shares during the period. Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter worth approximately $1,575,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in Corbus Pharmaceuticals during the 2nd quarter worth approximately $760,000. Institutional investors own 27.84% of the company’s stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded up $0.85 during trading hours on Tuesday, hitting $7.95. 2,032,816 shares of the stock traded hands, compared to its average volume of 622,266. The company has a market cap of $436.24, a price-to-earnings ratio of -12.82 and a beta of 175.11. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $5.30 and a 12 month high of $10.50.
Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.80 million during the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -0.6 EPS for the current fiscal year.
CRBP has been the topic of several recent research reports. ValuEngine downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Cantor Fitzgerald restated a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 20th. Noble Financial restated a “buy” rating and issued a $16.00 price target on shares of Corbus Pharmaceuticals in a research report on Friday, September 29th. Finally, BidaskClub downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Corbus Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $25.00.
In other Corbus Pharmaceuticals news, Director David P. Hochman purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $6.55 per share, for a total transaction of $32,750.00. Following the purchase, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,009,725. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Friday, November 10th. The shares were acquired at an average price of $7.08 per share, with a total value of $70,800.00. Following the purchase, the director now directly owns 459,500 shares in the company, valued at approximately $3,253,260. The disclosure for this purchase can be found here. Insiders bought a total of 25,336 shares of company stock valued at $175,632 in the last quarter. 11.90% of the stock is currently owned by company insiders.
WARNING: This piece was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.truebluetribune.com/2018/01/03/corbus-pharmaceuticals-holdings-inc-crbp-position-cut-by-perceptive-advisors-llc.html.
Corbus Pharmaceuticals Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.